In Vitro & In Vivo Diagnostic Substances — Ranked by Revenue
SIC 2835 · Annual figures from SEC 10-K filings
These rankings show the largest In Vitro & In Vivo Diagnostic Substances companies by revenue, based on the most recent fiscal year data reported in their annual 10-K filings with the SEC. Only companies with XBRL-tagged financial data are included. Use the tabs below to switch between revenue, net income, and total assets.
| # | Company | Revenue | Fiscal Year |
|---|---|---|---|
| 1 | QuidelOrtho Corp QDEL | $2.73B | FY2025 |
| 2 | MYRIAD GENETICS INC MYGN | $824.50M | FY2025 |
| 3 | IDEXX LABORATORIES INC /DE IDXX | $506.12M | FY2017 |
| 4 | NEOGEN CORP NEOG | $98.85M | FY2017 |
| 5 | Lantheus Holdings, Inc. LNTH | $81.24M | FY2017 |
| 6 | Intellia Therapeutics, Inc. NTLA | $67.67M | FY2025 |
| 7 | Alpha Teknova, Inc. TKNO | $40.52M | FY2025 |
| 8 | IMMUCELL CORP /DE/ ICCC | $27.64M | FY2025 |
| 9 | Aspira Women's Health Inc. AWHL | $9.22M | FY2025 |
| 10 | BIOMERICA INC BMRA | $5.79M | FY2017 |
| 11 | Insight Molecular Diagnostics Inc. IMDX | $4.06M | FY2025 |
| 12 | VOLITIONRX LTD VNRX | $1.73M | FY2025 |
| 13 | Q/C TECHNOLOGIES, INC. QCLS | $1.58M | FY2019 |
| 14 | Celldex Therapeutics, Inc. CLDX | $1.55M | FY2025 |
| 15 | Cardio Diagnostics Holdings, Inc. CDIOW | $14,825 | FY2025 |
| 16 | BURZYNSKI RESEARCH INSTITUTE INC BZYR | $0 | FY2025 |
| 17 | ACHIEVE LIFE SCIENCES, INC. ACHV | $0 | FY2019 |